Targeting EHMT2 overcomes 5-fluorouracil resistance in colorectal cancer by modulating cell cycle and apoptosis
Abstract 5-Fluorouracil (5-FU) is a first-line chemotherapy commonly used to treat colorectal cancer (CRC). However, the development of acquired resistance to 5-FU remains a significant clinical challenge, and the underlying epigenetic mechanisms are not fully understood. In this study, we demonstra...
Tallennettuna:
| Päätekijät: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Nature Publishing Group
2026-05-01
|
| Sarja: | Signal Transduction and Targeted Therapy |
| Linkit: | https://doi.org/10.1038/s41392-026-02692-7 |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|
